Polaryx Therapeutics is preparing to start its Phase 2 SOTERIA [...]

The FDA has granted Fast Track designation to Erasca’s investigational [...]

Aravax’s PVX108 has received FDA Fast Track designation as the [...]

HAYA Therapeutics has received FDA Fast Track designation for HTX-001, [...]

The US FDA has granted Fast Track Designation to SOTIO [...]

As Rare Disease Day 2026 shines a spotlight on patients [...]

Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

Cidara Therapeutics has received Breakthrough Therapy designation from the US [...]

Nanoscope Therapeutics has initiated a rolling submission for its Biologics [...]

Protagonist and Takeda have shared full 32-week results from the [...]